The CTG-Industry Collaborative Trials (CTG-ICT) from the National Medical Research Council (NMRC) of Singapore supports clinicians to carry out clinical trials for the development of novel therapies, interventions and diagnostics, focusing on healthcare needs. The CTG is open to applications in all research areas. Applications are assessed based on scientific merit at the international level and relevance to Singapore, but should prioritisation be required between meritorious applications, the following seven disease areas have been identified as national priorities for research:
- Cancers and neoplasms
- Cardiovascular
- Eye
- Infection
- Mental health
- Metabolic and endocrine
- Neurological
The CTG-Industry Collaborative Trials (CTG-ICT) scheme supports collaborations between clinician and industry, with both sides contributing intellectual inputs and funds to conduct the trials on novel or pre-existing drugs/medical device/interventions for new indications. The scheme will cover up to 30% of the Total Projects Costs inclusive of 30% indirect costs. Funding quantum for each project is capped at $4.94M per project and for a duration of up to 5 years.
Applications are assessed continuously and applicants may submit a letter of interest at any time, with a final deadline of August 1, 2025.